During the past decade, Praxis Fuer Internistische Haematologie / Onkologie conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Praxis Fuer Internistische Haematologie / Onkologie" #1 sponsor was "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 2 trials, followed by "iOMEDICO AG" with 2 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "Elevation Oncology" with 1 trials sponsored and "Heinrich-Heine University, Duesseldorf" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Praxis Fuer Internistische Haematologie / Onkologie" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Austrian Breast Cancer Study Group" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "ETOP IBCSG Partners Foundation" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Praxis Fuer Internistische Haematologie / Onkologie" are "Leukemia" (2 trials), "Lymphoma" (2 trials), "Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC" (1 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Praxis Fuer Internistische Haematologie / Onkologie" in a lesser frequency.

Most popular intervention types in "Praxis Fuer Internistische Haematologie / Onkologie" are "Drug" (7 trials), "Biological" (4 trials), "Radiation" (4 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (4 trials), "doxorubicin hydrochloride" (3 trials), "radiation therapy" (3 trials), "filgrastim" (2 trials) and "prednisone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Praxis Fuer Internistische Haematologie / Onkologie" are 8 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Praxis Fuer Internistische Haematologie / Onkologie". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Praxis Fuer Internistische Haematologie / Onkologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Praxis Fuer Internistische Haematologie / Onkologie, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".

Praxis Fuer Internistische Haematologie / Onkologie has several departments that took part in Clinical trials: "Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis" - 4 trials